This article summarizes available data for the use of CYP3A4 inhibitors with midostaurin for acute myeloid leukemia.
Danielle Schlafer, PharmD, BCOP
Advertisement
Articles by Danielle Schlafer, PharmD, BCOP
Advertisement
Latest Updated Articles
Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid LeukemiaPublished: July 16th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type
2
FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC
3
How Can Oncology Staffing Shortages Be Remedied?
4
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
5
